Highlights:

• Three ASX-listed companies recorded sharp gains as investors responded to major corporate developments and FY26 financial results.
• Takeover speculation, operational improvements and stronger forward guidance emerged as key catalysts behind the market moves.
• Investors are now watching whether these developments can translate into sustained earnings growth and further shareholder value.

Australian investors witnessed a powerful wave of buying on 18 August 2026, with Reliance Worldwide Corporation Limited (ASX: RWC), CSL Limited (ASX: CSL), and Judo Capital Holdings Limited (ASX: JDO) emerging among the session’s standout performers. RWC surged 24.653% to $4.500, CSL jumped 17.251% to $157.820, while Judo Capital gained 16.939% to $1.070. The sharp moves were driven by a combination of corporate activity, full-year financial results, improving operational metrics and forward-looking guidance.

RWC delivered the most dramatic catalyst after revealing an unsolicited, non-binding proposal from Brookfield to acquire the company for AU$4.75 per share, alongside its FY26 results. CSL’s rally came as investors looked beyond substantial reported impairments towards its transformation program, cash generation and FY27 growth outlook. Meanwhile, Judo Capital’s strong profit growth, expanding lending portfolio, improved operating leverage and upbeat FY27 guidance provided another reason for investors to reassess the stock.

RWC Takes Centre Stage as Brookfield Offer Changes the Equation

Reliance Worldwide Corporation Limited emerged as one of the standout performers on 18 August 2026, with its share price advancing 24.653% to $4.500. The stock rallied strongly after RWC announced its FY26 results and disclosed an unsolicited, non-binding takeover proposal from Brookfield Capital Partners LLC, valuing the company at AU$4.75 per share.

The proposal arrived against a challenging financial backdrop. RWC reported FY26 net sales of US$1,305.6 million, down 0.7% year-on-year, while adjusted NPAT declined 15.3% to US$125.1 million. Adjusted EBITDA fell 12.8% to US$242.1 million, with US tariffs, elevated copper costs, weaker volumes across the Americas and EMEA, and broader cost inflation weighing on profitability. These pressures reduced the adjusted EBITDA margin to 18.5%, compared with 21.1% in the previous corresponding period.

However, RWC continued to demonstrate strong cash generation. Operating cash flow reached US$263.4 million, representing 108.8% conversion of adjusted EBITDA, while net debt fell by US$88.2 million to US$243.4 million.

The takeover proposal has added further momentum to the company’s growth story. The Brookfield proposal has led RWC to suspend its on-market buy-back and withhold a final FY26 dividend. Should the proposed transaction fail to proceed, RWC could revisit its dividend policy and share buy-back program during calendar 2027. Looking ahead, the company anticipates FY27 sales growth in the mid- to high-single-digit range, supported by new product launches and pricing initiatives, while EBITDA margins are expected to remain broadly stable compared with FY26.

CSL Sparks a Healthcare Rebound

CSL Limited also attracted significant buying interest, rising 17.251% to $157.820. The move came after the healthcare major released its FY26 full-year results on 18 August 2026.CSL delivered revenue of US$15.797 billion, broadly stable in constant-currency terms but down 1% on the reported basis. Underlying NPATA came in at US$3.098 billion, while underlying NPAT was US$2.837 billion. Reported NPAT swung to a loss of US$2.579 billion after substantial restructuring and impairment charges, including US$7.1 billion of impairment and related costs and US$0.8 billion of restructuring costs.

Despite the headline statutory loss, the underlying picture contained several encouraging signals. CSL highlighted robust immunoglobulin demand, strong uptake of ANDEMBRY and HEMGENIX, and growth in seasonal influenza vaccines. The company also realised US$176 million in cost savings through its transformation program, with disciplined reinvestment into commercial and pipeline initiatives.

The FY27 outlook provides another potential catalyst. CSL expects Behring to return to mid-single-digit revenue growth, supported by immunoglobulin demand and continued ANDEMBRY uptake. Seqirus is expected to deliver low-single-digit revenue growth, while Vifor remains under pressure from generic competition. At group level, FY27 revenue is expected to be broadly in line with FY26 at constant currency, while underlying NPAT is forecast to increase by approximately 5%. The company also plans to continue its A$1.1 billion share buy-back.CSL has also maintained its dividend, with an ordinary distribution of US$1.62 per share announced on 18 August 2026.

Judo Capital Gains Momentum as Profit and Lending Accelerate

Judo Capital Holdings Limited completed the trio of major movers, climbing 16.939% to $1.070 on 18 August 2026. The specialist SME lender reported statutory operating income of $522 million, up 24%, while statutory profit attributable to shareholders increased 29% to $111 million.The full-year numbers reveal substantial expansion in the underlying banking franchise. Gross loans and advances increased 18% to $14.7 billion, while deposits rose 24% to $12.2 billion. Judo’s cost-to-income ratio improved sharply from 52.4% to 45.3%, demonstrating stronger operating leverage. Net interest margin increased 20 basis points to 3.13%, reaching 3.23% in the second half.

There was, however, a cautionary element. Impairment expense increased to $117.7 million from $75.5 million, reflecting higher individually assessed provisions and changes to forward-looking economic assumptions.

Nevertheless, management expects further growth. FY27 guidance calls for disciplined above-system loan growth, broadly stable NIM, continued improvement in the cost-to-income ratio and credit costs broadly consistent with FY26. Profit before tax is forecast at $210–220 million, representing approximately 25–31% growth, while ROE is expected to reach around 8%.

Three Different Catalysts Behind One Powerful Rally

The sharp gains across RWC, CSL and JDO highlight three very different market catalysts. RWC has been propelled by corporate takeover speculation alongside its FY26 results, CSL is being reassessed on the potential benefits of restructuring and renewed growth, while Judo is attracting attention for its expanding loan book, improving operating leverage and stronger FY27 earnings outlook.

The common thread is that investors appear to be looking beyond headline numbers and focusing on what could come next. For RWC, the key question is whether Brookfield’s proposal progresses. For CSL, the market will watch whether transformation benefits translate into sustainable earnings growth. For Judo, credit quality and impairment trends will remain important as lending continues to expand.

Market Outlook

The three stocks demonstrate how quickly sentiment can shift when corporate events, operational improvements and forward guidance converge. While the immediate share-price reactions have been substantial, the durability of these rallies will ultimately depend on execution, earnings delivery and the progression of each company’s respective catalyst.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au